Relmada Corp - RLMD Real Price to Acquire Entire Company

Official company branding of relmada.com (RLMD)

The market price for Relmada Therapeutics (RLMD) on the GURU.Markets platform, as confirmed by this chart, is 124.68. The business relies on US laboratories, while drug development is outsourced to external CDMO facilities. Relmada Therapeutics occupies a niche segment in the treatment of major depressive disorder, yet faces the threat of share devaluation and financial losses due to the risks of failure in the final trials of its lead drug candidate.

RLMD (Relmada Corp) Total Company Value history from 11/23/2025 to 10/28/2026

Relmada Therapeutics (RLMD) - metric breakdowns and financial figures

- price and consensus price forecast:
Price Chart Relmada Therapeutics Inc|RLMD - Price Target Chart
- market capitalization data:
Market Valuation Relmada Therapeutics|RLMD - Enterprise Value
- book capitalization data:
Equity per Share Relmada Therapeutics|RLMD - Company Book Value|Capitalization to Book Value Ratio relmada.com|RLMD - Company Total Assets
- debt and liquidity data:
Debt to Capital Relmada Therapeutics|RLMD - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital relmada.com|RLMD - Company Debts|Debt to Net Assets Ratio Relmada Therapeutics|RLMD - Company Long-Term Debt|Short-Term Debt Relmada Therapeutics
Comprehensive company analysis:Relmada Therapeutics Inc (RLMD)
Mass-produced product of Relmada Therapeutics

Investors assess the enterprise value to stress-test assets. Relmada Therapeutics (RLMD) is currently in the clinical trial stage without stable sales. This market price indicator, adjusted for debt, sums the market capitalization and liabilities while subtracting cash and cash equivalents. This methodology determines the actual cost of a full buyout of the issuer. For this specific business model, the metric reflects the cost of raised capital.

Direct competitors

Biogen Inc - Total Company Value|NBIX: Total Company Value|RGC - Real Price to Acquire Entire Company|Enterprise Value Axsome Therapeutics|ACAD (acadia-pharm.com) - Business Value|Total Company Value Xenon (XENE)|Business Value Viking Therapeutics Inc|Supernus Pharma - Enterprise Value|Total Enterprise Value Catalyst Corp CPRX|Real Price to Acquire Entire Company DNLI (Denali Therapeutics)|harmonybiosciences.com - Enterprise Value|Total Company Value Biohaven (BHVN)|AMLX: Value Adjusted for Debt and Cash|Total Company Value TRVI|PRAX (Praxis Corp) - Total Enterprise Value|AVXL - Total Company Value|Value Adjusted for Debt and Cash ceribell.com|Prothena Biosciences - Enterprise Value|Total Enterprise Value ALEC (alector.com)|Total Company Value Annexon Inc. ANNX|Omeros Corp - Total Company Value|NGNE: Total Company Value|ACIU - Real Price to Acquire Entire Company|VYGR: Enterprise Value|Neumora (NMRA) - Enterprise Value|Enterprise Value Scilex Holding Co. (SCLX)|Business Value Tevogen Bio Inc.|Enterprise Value ACOG|Enterprise Value Cognition Therapeutics Inc. CGTX|Real Price to Acquire Entire Company Inhibikase Therapeutics, Inc.|SAVA - Value Adjusted for Debt and Cash|Real Price to Acquire Entire Company Assertio Therapeutics ASRT|COYA - Aggregate Business Value|Enterprise Value vistagen.com VTGN|Ovid Therapeutics (OVID) - Value Adjusted for Debt and Cash|Enterprise Value ABOS (Acumen Pharmaceuticals, Inc.)|Total Enterprise Value CRVO|Alterity Therapeutics (ATHE) - Total Company Value|Value Adjusted for Debt and Cash clene.com (CLNN)|Enterprise Value PEPG (PepGen)|Jupiter Neurosciences, Inc. - Enterprise Value|Total Company Value Annovis Bio|GRCE - Full Business Value|Enterprise Value AIFF|Total Enterprise Value Klotho Neurosciences|NRSN (NeuroSense Therapeutics Ltd) - Real Price to Acquire Entire Company|Enterprise Value revivapharma.com (RVPH)|Real Price to Acquire Entire Company MetaVia Inc|Aggregate Business Value NeurAxis Inc. (NRXS)|Enterprise Value HSDT|Company Buyout Price Passage Bio Inc. PASG|NEUP: Enterprise Value|NERV: Real Price to Acquire Entire Company|Athira Pharma - Total Company Value|ADXN (Addex Therapeutics Ltd.) - Company Buyout Price|ALZN - Total Company Value|Value Adjusted for Debt and Cash CYCN|Total Company Value Protagenic Therapeutics (PTIX)|Total Company Value KTTA (pasitheaclinics.com)|Cortigent - Total Company Value|Real Price to Acquire Entire Company Avenue Therapeutics Inc. ATXI|Brainstorm Cell Therapeutics, Inc. (BCLI) - Enterprise Value|CARA: Business Value|Total Company Value Chromocell Therapeutics|Eliem Therapeutics Inc. (ELYM) - Business Value|Enterprise Value ITCI (Intra-Cellular Therapies Inc.)|Total Enterprise Value Longboard Pharmaceuticals Inc (LBPH)|Real Price to Acquire Entire Company MRNS|Enterprise Value NKGN (NKGen Biotech Corp)|Total Company Value NeuroBo Pharmaceuticals|sagerx.com - Value Adjusted for Debt and Cash|SNPX (Synaptogenix) - Total Company Value|TRVN: Total Enterprise Value|Total Company Value vigilneuro.com VIGL|anewmeds.com (WENA) - Value Adjusted for Debt and Cash|Enterprise Value CERE (Cerevel Therapeutics)